Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $18.4 million.

  • Xeris Biopharma Holdings' Share-based Compensation rose 12.93% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 17.99%. This contributed to the annual value of $18.4 million for FY2024, which is 71.36% up from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Share-based Compensation is $18.4 million, which was up 71.36% from $10.7 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Share-based Compensation peaked at $18.4 million during FY2024, and registered a low of $8.3 million during FY2020.
  • In the last 3 years, Xeris Biopharma Holdings' Share-based Compensation had a median value of $12.2 million in 2022 and averaged $13.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 11.88% in 2023, then surged by 71.36% in 2024.
  • Xeris Biopharma Holdings' Share-based Compensation (Yearly) stood at $8.3 million in 2020, then skyrocketed by 37.57% to $11.4 million in 2021, then grew by 6.84% to $12.2 million in 2022, then declined by 11.88% to $10.7 million in 2023, then surged by 71.36% to $18.4 million in 2024.